From a locally sourced meal service company to stem cell research and a balance measuring device, this week's innovators are ones to know in the health industry. Courtesy photos

More and more Americans are focusing on their health, from eating right to experimenting with new treatments or devices. These three Houston innovators are riding the coattails of this health-focused movement with their startups. With advances in technology and the movement only growing faster and faster, you'd better keep your eye on these Houston innovators.

Marla Murphy, founder of The Blonde Pantry

Courtesy of The Blonde Pantry

Marla Murphy didn't feel like she was doing enough to promote health and wellness with her platform, The Blonde Pantry. So, she expanded it to incorporate locally sourced produce and easy-to-make recipes she gets ready every weekend to deliver to her members by Monday.

"It's not about selling meals and moving on, I want this to be a lifestyle company that is really founded and has deep roots in Houston," says Murphy in a InnovationMap story.

Murphy tells InnovationMap that in the next year she hopes to expand into the retail space and find a bigger commercial kitchen to function as their own. She also hopes to partner with companies outside of food and continue to nourish lives in someway.

David Eller, chairman, co-founder and CEO of Celltex

Courtesy of Celltex

Stem cell treatment is personal to David Eller, chairman, co-founder and CEO of Celltex. Eller had the treatment in hopes of resolving pain from a college football injury.

"I would go to work and put four to six Advil in my pocket," Eller says in an InnovationMap story about Celltex's technology. Within months, he stopped needing those pills.

Houston-based Celltex tracks its progress with its patients. Eighty-three percent of multiple sclerosis patients have reported improvement of symptoms specific to their disease, as have 73 percent of Parkinson's sufferers. But the staggering fact is that 100 percent of 58 respondents with rheumatoid arthritis say they have benefited.

Katharine Forth, founder and CEO of Zibrio

Courtesy of Zibrio

Katharine Forth has used a technology she developed with her colleague at NASA to measure balance in astronauts to create a device that any terrestrial human can now use from the comfort of their own homes.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says in an InnovationMap article about Zibrio, The Balance Company. Zibrio, The Balance Company.

Zibrio is now a finalist for the 2019 SXSW Pitch in the health and wearables category and will take its balance technology to the stage in March.

Balancing is important throughout your life, and Zibrio has the tools and tips for you to use to stay centered. Pexels

Houston medical devices company using NASA balancing technology prepares for commercial launch

From space to marketplace

In her postdoctoral work at NASA, Katharine Forth and her colleague were tasked with finding a new way to track the balance of astronauts on the moon.

"The machines typically used for balance measurement can be as large as a telephone booth, so we invented a new way to measure postural control using a much smaller mechanism that fit inside a moon boot," Forth says.

She didn't know it at the time, but working on this technology would lead her to create Zibrio, The Balance Company with her colleague, Erez Lieberman Aiden.

Zibrio is a health company that aims to be the gold standard of measuring balance. The Zibrio scale calculates users' weight like a typical scale and rates their balance on scale of 1 to 10.

The scale gathers data from your weight, your postural control, your muscles and other factors to calculate the rating. Andrea Case-Rogers, chief experience officer at Zibrio, describes a perfect rating of 10 as elusive for most, or "Simone Biles on a good day."

After seeing their rating, users can identify any problems and start taking steps to improve their balance. Zibrio will also come with a smartphone app, so users can track their balance, any fluctuations and progress over a long-term period.

By using the scale and app together, users can gain a greater understand of what in their lifestyle is helping versus hurting their balance.

From space to the marketplace
After co-founding Zibrio together in 2015, Forth and Aiden have taken the company a long way since then.

Zibrio is a finalist for the 2019 SXSW Pitch in the health and wearables category. In 2015, the company was part of the Texas Medical Center's TMCx medical devices cohort. Both programs highlight the innovative technology being used as well as the big impact that Zibrio could have for both consumers and clinicians.

Zibrio already has conducted clinical trials all over Houston by working with Memorial Hermann and UT Physicians, and the company is currently focused on fundraising. Forth and her team of five will use these funds to get the scale and smartphone app consumer-ready and launched.

The commercial launch for both the scale and app is planned for later this year.

"We're currently finalizing the design with the manufacturer, so they can make the scale available commercially," Forth says. "Since 2015, we've been fundraising, building prototype scales and conducting clinical trials."

Finding balance at any age
A common misconception is that our balance deteriorates in older age. In actuality, a lifetime of behavior and activity affects our balance in later years. Falls are the leading cause of accidental death and unexpected injuries in older adults.

"If you have been mostly sedentary your whole life, by the time you hit your later years, your lower limb strength is weakened affecting your ability to move." Forth says, "so many factors feed into your balance, which means there are so many things that can be done to lower your fall risk."

When Forth and her team ran a balance program at a senior living facility, they halved the number of falls in two years. By creating an awareness of balance, they were able to drive changed behaviors in the seniors, in turn, improving their balance.

According to Case-Rogers, Zibrio is bringing the balance conversation to people in 60s and 70s who want to keep their lifestyle and not deal with mobility and health issues later. They want to show investors that there is a market for wellness product like Zibrio among older people.

Zibrio will sponsor the National Senior Games, the largest multi-sport competition for seniors in the world, this summer in Albuquerque. With over 10,000 athletes, Forth and her team are excited to introduce Zibrio to a larger audience.

Forth firmly believes balance measurements should be a part of routine wellness exams and home self-monitoring, especially in later years.

"When athletes stand on a scale and see their number, it's like a light goes on in their heads and they realize how important balance is," says Forth. "That's what I love, we have this great product that opens up the conversation about and is really helping people in middle age and beyond."

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”